ZA201200227B - Gpr119 agonists - Google Patents

Gpr119 agonists

Info

Publication number
ZA201200227B
ZA201200227B ZA2012/00227A ZA201200227A ZA201200227B ZA 201200227 B ZA201200227 B ZA 201200227B ZA 2012/00227 A ZA2012/00227 A ZA 2012/00227A ZA 201200227 A ZA201200227 A ZA 201200227A ZA 201200227 B ZA201200227 B ZA 201200227B
Authority
ZA
South Africa
Prior art keywords
gpr119 agonists
gpr119
agonists
Prior art date
Application number
ZA2012/00227A
Other languages
English (en)
Inventor
David Gene Barrett
Jeffrey Bernard Franciskovich
Kumiko Takeuchi
Melendo Ana Belen Bueno
Bin Liu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43449712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201200227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ZA201200227B publication Critical patent/ZA201200227B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
ZA2012/00227A 2009-07-15 2012-01-11 Gpr119 agonists ZA201200227B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382114 2009-07-15
US24544509P 2009-09-24 2009-09-24
PCT/US2010/041645 WO2011008663A1 (en) 2009-07-15 2010-07-12 Gpr119 agonists

Publications (1)

Publication Number Publication Date
ZA201200227B true ZA201200227B (en) 2013-06-26

Family

ID=43449712

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00227A ZA201200227B (en) 2009-07-15 2012-01-11 Gpr119 agonists

Country Status (24)

Country Link
US (1) US8207344B2 (enExample)
EP (1) EP2454251A1 (enExample)
JP (1) JP5715127B2 (enExample)
KR (1) KR101365854B1 (enExample)
CN (1) CN102471313B (enExample)
AR (1) AR077638A1 (enExample)
AU (1) AU2010273642B2 (enExample)
BR (1) BRPI1015921A2 (enExample)
CA (1) CA2764906C (enExample)
CO (1) CO6480977A2 (enExample)
CR (1) CR20120012A (enExample)
DO (1) DOP2012000006A (enExample)
EA (1) EA020540B1 (enExample)
EC (1) ECSP12011606A (enExample)
IL (1) IL216776A0 (enExample)
MA (1) MA33428B1 (enExample)
MX (1) MX2012000704A (enExample)
NZ (1) NZ597125A (enExample)
PE (1) PE20121045A1 (enExample)
SG (1) SG177646A1 (enExample)
TN (1) TN2012000002A1 (enExample)
TW (1) TWI429634B (enExample)
WO (1) WO2011008663A1 (enExample)
ZA (1) ZA201200227B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
MX2013003184A (es) 2010-09-22 2013-06-07 Arena Pharm Inc Moduladores del receptor gpr119 y el tratamiento de transtornos relacionados con el mismo.
WO2012135570A1 (en) * 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2693882B1 (en) 2011-04-08 2017-06-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2012170702A1 (en) * 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
CA2838079A1 (en) 2011-06-16 2012-12-20 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
EP2760855B1 (en) 2011-09-30 2017-03-15 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds as well as their use in treating type-2 diabetes
US9018200B2 (en) 2011-10-24 2015-04-28 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as GPR119 agonists
WO2013062835A1 (en) * 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Substituted piperidinyl compounds useful as gpr119 agonists
US9018224B2 (en) 2011-11-15 2015-04-28 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds useful as GPR119 agonists
BR112014031091A2 (pt) * 2012-06-12 2017-08-22 Chong Kun Pharmaceutical Corp Derivados de piperidina para agonista de gpr119
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014052619A1 (en) * 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
HRP20191246T1 (hr) * 2013-11-26 2019-12-27 Chong Kun Dang Pharmaceutical Corp. Derivati amida za gpr119 agonist
KR101651505B1 (ko) * 2014-05-02 2016-08-29 현대약품 주식회사 싸이클로 헥센 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
PL3310760T3 (pl) 2015-06-22 2023-03-06 Arena Pharmaceuticals, Inc. Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
AU2019280822A1 (en) 2018-06-06 2021-01-07 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102558155A (zh) * 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
CA2661371A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyrimidine compounds for treating gpr119 related disorders
US7638541B2 (en) * 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
CA2697551C (en) 2007-09-20 2013-03-12 Irm Llc Piperidine derivatives as modulators of gpr119 activity

Also Published As

Publication number Publication date
MA33428B1 (fr) 2012-07-03
NZ597125A (en) 2013-08-30
TN2012000002A1 (en) 2013-09-19
AU2010273642B2 (en) 2014-03-13
AU2010273642A1 (en) 2012-01-19
PE20121045A1 (es) 2012-08-09
CO6480977A2 (es) 2012-07-16
MX2012000704A (es) 2012-03-07
EP2454251A1 (en) 2012-05-23
IL216776A0 (en) 2012-03-01
AR077638A1 (es) 2011-09-14
TWI429634B (zh) 2014-03-11
EA201270169A1 (ru) 2012-06-29
TW201114757A (en) 2011-05-01
DOP2012000006A (es) 2012-01-31
US8207344B2 (en) 2012-06-26
CN102471313B (zh) 2014-06-04
SG177646A1 (en) 2012-02-28
JP2012533546A (ja) 2012-12-27
US20110015199A1 (en) 2011-01-20
BRPI1015921A2 (pt) 2016-04-26
CN102471313A (zh) 2012-05-23
ECSP12011606A (es) 2012-02-29
CA2764906C (en) 2014-06-10
WO2011008663A1 (en) 2011-01-20
JP5715127B2 (ja) 2015-05-07
KR20120024964A (ko) 2012-03-14
CA2764906A1 (en) 2011-01-20
EA020540B1 (ru) 2014-11-28
KR101365854B1 (ko) 2014-02-21
CR20120012A (es) 2012-03-28

Similar Documents

Publication Publication Date Title
IL216776A0 (en) Gpr119 agonists
EP2474540A4 (en) GPR119 AGONIST
EP2311822A4 (en) GPR119 AGONIST
IL208919A0 (en) Gpr119 receptor agonists
DK2457337T3 (en) Specialtilpasset impuls-burst
DK2442650T4 (en) Sublingualt apomorfin
EP2460094A4 (en) SELECTIVITY-BASED INTERMEDIATE STORAGE WITH OPTIMIZED QUERY PLAN
EP2515891A4 (en) 3-keto-N-propargyl-1-aminoindan
IL218649A0 (en) Oxytocin receptor agonists
IL220526A0 (en) Kokumi-imparting agent
ZA201702958B (en) Novel npr-b agonists
IL220527A0 (en) Kokumi-imparting agent
GB0708226D0 (en) Y-receptor agonists
DK2464943T3 (en) Systemintegration
GB0921329D0 (en) Biomarker
IL217333A0 (en) Biomarker
GB2469272B (en) Block
GB0912175D0 (en) Biomarker
GB2474717B (en) Pinsticks
GB0903710D0 (en) Holder
EP2510125A4 (en) HYPER PRIMER
HK1164879A (en) Gpr119 agonists
AU4926P (en) Bonscalib Scaevola aemula
AU4240P (en) Tuckerbox xTriticosecale
AU4924P (en) Bonscablue Scaevola aemula